LucidQuest’s Post

Thoughts on this? >> Valneva pays LimmaTech $10M for clinical-stage Shigella vaccine >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #competitivemarketing #healthcare

Thoughts on this? >> Takeda spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #competitivemarketing #healthcare

Thoughts on this? >> FDA puts Novavax's phase 3 plan for pair of vaccine programs on hold over nerve disease case >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #competitivemarketing

Thoughts on this? >> Takeda spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #competitivemarketing

Thoughts on this? >> FDA puts Novavax's phase 3 plan for pair of vaccine programs on hold over nerve disease case >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #pharmaceutical #pharma #healthcare

Thoughts on this? >> Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #competitivemarketing #pharmaceutical #healthcare

#News: Sanofi announced a deal worth up to $1.4 billion with Novavax on Friday for its #COVID19vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business. The French pharma is dropping $500 million upfront for #Novavax’s #COVID19 #vaccine, with the goals of co-commercializing its current formulation as well as developing a combination vaccine for #COVID and #flu. An additional $700 million is up for grabs in milestone payments. Along with another potential $200 million in milestones for additional vaccines made with Novavax’s Matrix #adjuvanttechnology, deal totals $1.4 billion—more than double the #biotech’s current market cap of $627 million. Read more from BioSpace 👇🏽 https://lnkd.in/dHCXrgcb

Thoughts on this? >> YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #competitivemarketing

AstraZeneca Phases Out Its COVID-19 Vaccine Globally AstraZeneca is discontinuing its COVID-19 vaccine due to falling demand and the emergence of new vaccines. Concerns over rare side effects, such as blood clots, have also impacted its reputation. The company is facing legal challenges and is transitioning to other pharmaceutical innovations. This highlights the need for continuous innovation in vaccine technology and emphasizes the role of legal considerations in pharmaceutical companies' strategies. The withdrawal reflects shifts in global vaccine strategies and serves as a critical analysis point for future pandemic responses and vaccine development strategies. For more details please click the link! https://lnkd.in/dev5v7P2 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #TBVaccines #GlobalHealth #Immunotherapy #BoosterVaccines #Healthcare #Research #PublicHealth #Pharmaceuticals #VaccineDevelopment #DiseasePrevention